首页> 外文期刊>Disease markers >Systematic Review and Meta-Analysis of Diagnostic Accuracy of miRNAs in Patients with Pancreatic Cancer
【24h】

Systematic Review and Meta-Analysis of Diagnostic Accuracy of miRNAs in Patients with Pancreatic Cancer

机译:胰腺癌患者miRNA诊断准确性的系统评价和Meta分析

获取原文
获取外文期刊封面目录资料

摘要

Background. It is reported that miRNAs are aberrantly expressed in patients with pancreatic cancer. However, the diagnostic value of miRNAs in pancreatic cancer remains controversial. The meta-analysis was to access diagnostic accuracy of miRNAs in pancreatic cancer. Methods. PubMed, Scopus, Web of Science, Chinese National Knowledge Infrastructure (CNKI), WANFANG Data, China Biomedical Literature Database (CBM), and VIP databases were retrieved up to June 30, 2016, to collect articles concerning the diagnosis of miRNAs in pancreatic cancer. The methodological quality of each study was assessed by the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). This meta-analysis was conducted using RevMan5.0, MetaDiSc 1.4, and Stata 12.0 software. Results. There are 40 articles including 109 studies. The pooled SEN was 0.81 (95% CI, 0.80–0.82), the pooled SPE was 0.78 (95% CI, 0.77–0.79), the pooled
机译:背景。据报道,miRNA在胰腺癌患者中异常表达。但是,miRNA在胰腺癌中的诊断价值仍存在争议。荟萃分析旨在获得miRNA在胰腺癌中的诊断准确性。方法。截至2016年6月30日,已检索PubMed,Scopus,科学网络,中国国家知识基础设施(CNKI),WANFANG数据,中国生物医学文献数据库(CBM)和VIP数据库,以收集有关胰腺癌中miRNA诊断的文章。 。每个研究的方法学质量均通过诊断准确性研究的质量评估(QUADAS-2)进行评估。这项荟萃分析使用RevMan5.0,MetaDiSc 1.4和Stata 12.0软件进行。结果。有40篇文章,其中包括109篇研究。合并的SEN为0.81(95%CI,0.80–0.82),合并的SPE为0.78(95%CI,0.77–0.79),合并的

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号